HN1999000097A - Terapia de combinacion para la fragilidad muscoloesqueletica - Google Patents

Terapia de combinacion para la fragilidad muscoloesqueletica

Info

Publication number
HN1999000097A
HN1999000097A HN1999000097A HN1999000097A HN1999000097A HN 1999000097 A HN1999000097 A HN 1999000097A HN 1999000097 A HN1999000097 A HN 1999000097A HN 1999000097 A HN1999000097 A HN 1999000097A HN 1999000097 A HN1999000097 A HN 1999000097A
Authority
HN
Honduras
Prior art keywords
muscoloskeletal
fragility
combination therapy
ghs
serm
Prior art date
Application number
HN1999000097A
Other languages
English (en)
Inventor
Pfizer Products Inc
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HN1999000097A publication Critical patent/HN1999000097A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMBINACION FARMACEUTICA DE UN MODULADOR DEL RECEPTOR DE ESTROGENOS SELECTIVO (SERM) Y UN SECRETAGOGO DE LA HORMONA DEL CRECIMIENTO (GHS) QUE ESTIMULA LA FORMACION DE HUESO, AUMENTA LA MASA OSEA, DISMINUYE LOS NIVELES DE LIPIDOS SERICOS Y AUMENTA LA MASA MUSCULAR.
HN1999000097A 1998-06-16 1999-06-15 Terapia de combinacion para la fragilidad muscoloesqueletica HN1999000097A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
HN1999000097A true HN1999000097A (es) 1999-11-03

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1999000097A HN1999000097A (es) 1998-06-16 1999-06-15 Terapia de combinacion para la fragilidad muscoloesqueletica

Country Status (30)

Country Link
EP (1) EP1087764A1 (es)
JP (1) JP2002518326A (es)
KR (1) KR20010052852A (es)
CN (1) CN1301160A (es)
AP (1) AP9901582A0 (es)
AR (1) AR018869A1 (es)
AU (1) AU4054799A (es)
BG (1) BG105041A (es)
BR (1) BR9911324A (es)
CA (1) CA2335134A1 (es)
CO (1) CO5070587A1 (es)
EA (1) EA200001186A1 (es)
GT (1) GT199900087A (es)
HN (1) HN1999000097A (es)
HR (1) HRP20000859A2 (es)
HU (1) HUP0102505A3 (es)
ID (1) ID27599A (es)
IL (1) IL138630A0 (es)
IS (1) IS5691A (es)
MA (1) MA26652A1 (es)
NO (1) NO20006312D0 (es)
OA (1) OA11505A (es)
PA (1) PA8475901A1 (es)
PE (1) PE20000646A1 (es)
PL (1) PL344981A1 (es)
SK (1) SK18912000A3 (es)
TN (1) TNSN99124A1 (es)
TR (1) TR200003544T2 (es)
WO (1) WO1999065486A1 (es)
ZA (1) ZA993975B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360103A1 (en) * 1999-02-08 2000-08-17 Robert Sladek Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
DE60124616T2 (de) 2000-05-08 2007-09-13 Pfizer Products Inc., Groton Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2118080B1 (en) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
HUP0102505A3 (en) 2002-12-28
AR018869A1 (es) 2001-12-12
PE20000646A1 (es) 2000-08-05
AP9901582A0 (en) 1999-06-30
PA8475901A1 (es) 2000-05-24
ID27599A (id) 2001-04-12
KR20010052852A (ko) 2001-06-25
WO1999065486A1 (en) 1999-12-23
OA11505A (en) 2004-05-07
BG105041A (en) 2001-08-31
AU4054799A (en) 2000-01-05
SK18912000A3 (sk) 2001-10-08
IS5691A (is) 2000-10-27
MA26652A1 (fr) 2004-12-20
HUP0102505A2 (hu) 2001-11-28
IL138630A0 (en) 2001-10-31
BR9911324A (pt) 2001-04-03
NO20006312L (no) 2000-12-12
PL344981A1 (en) 2001-11-19
CA2335134A1 (en) 1999-12-23
NO20006312D0 (no) 2000-12-12
CN1301160A (zh) 2001-06-27
EP1087764A1 (en) 2001-04-04
JP2002518326A (ja) 2002-06-25
HRP20000859A2 (en) 2001-04-30
TNSN99124A1 (fr) 2005-11-10
TR200003544T2 (tr) 2001-04-20
CO5070587A1 (es) 2001-08-28
ZA993975B (en) 2000-12-15
EA200001186A1 (ru) 2001-06-25
GT199900087A (es) 2000-12-07

Similar Documents

Publication Publication Date Title
AP2001002264A0 (en) Sustained release formulations for growth hormone secretagogues.
BR9909903A (pt) Eficácia máxima de substâncias usadas para melhorar a saúde e bem-estar
MXPA05006670A (es) Administracion de capsaicinoides.
DE69920689D1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
UY26701A1 (es) Análogos de tetrahidroisoquinolina útiles como secretagogos de la hormona del crecimiento
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
AU2003301190A8 (en) Administration of capsaicinoids
BR0015188A (pt) Composições farmacêuticas
EP0653488A4 (en) RIBOZYME LOOPED IN HAIRPINS.
HUP0101427A2 (hu) Pezsgő készítmények
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
ES2158108T3 (es) Vacunacion in ovo contra la coccidiosis.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
HN1999000097A (es) Terapia de combinacion para la fragilidad muscoloesqueletica
AR013479A1 (es) Metodo para aumentar el volumen oseo utilizando agonistas de prostanoide f selectivos no naturales.
IS7065A (is) Áætlun um lyfjaskammta við meðferð og lyfjasamsetningar til getnaðarvarna í neyð
GT199900066A (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea.
HUP0101528A2 (hu) LHRH antagonisták és antiösztrogének alkalmazása termékenységi rendellenességek kezelésére
ES2136954T3 (es) Utilizacion de al menos un agua termal de vichy como antagonista de sustancia p.
ES2159357T3 (es) Derivados terpenoides (sarcodictinas) utiles como agentes antitumorales.
ES2187156T3 (es) Terapia antidepresiva.
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
ES2168562T3 (es) Medicamentos analgesicos a base de combinaciones con tramadol.
AR034037A1 (es) Inhibidor de aromatasa en dosis multiples para tratar la infertilidad
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.